Stockreport

Why Oculis Holding (OCS) Is Up 15.3% After FDA Breakthrough Status For Privosegtor In Optic Neuritis [Yahoo! Finance]

Oculis Holding AG  (OCS) 
PDF FDA Breakthrough Therapy designation for optic neuritis, supported by positive Phase 2 ACUITY data and the launch of the PIONEER registrational program in optic neuropat [Read more]